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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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WEDNESDAY, OCTOBER 19, 2016

Ionis Phase I Huntington’s disease trial at halfway
mark: ‘No surprises so far’ means good news
At its halfway mark, Ionis Pharmaceuticals' historic Huntington’s disease
Phase 1 gene-silencing clinical trial is on track to finish as scheduled in late
2017, company officials said in an interview on September 26.
“What we can say is that the trial is going well,” said Frank Bennett, Ph.D.,
Ionis senior vice president of research and the franchise leader for the
company’s neurology programs.
Dr. Bennett added that no “issues” have arisen so far in the Phase 1 safety
and tolerability study of its drug IONIS-HTTRx in patients with early HD.
IONIS-HTTRx aims to reduce the production of huntingtin protein in brain
cells. This approach, if it advances to Phases 2 and 3, may have the
potential to slow, halt or perhaps even reverse the progression of HD
symptoms. The trial began in September 2015, with participants in
England, Germany, and Canada.
The Ionis HD team explained that the Phase 1 trial is not assessing the
drug’s efficacy. Each patient in the trial receives the drug for just three
months – not long enough to gauge any impact on symptoms.
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Furthermore, the trial is “double-blinded”: trial participants, trial
administrators, and Ionis scientists do not know who is getting the drug or
a placebo. This insures that bias and other external factors don’t affect the
trial results.

► 2010 (26)
► 2009 (21)
► 2008 (7)
► 2007 (7)
► 2006 (4)
► 2005 (17)

About Me
GENE VERITAS

View my complete profile

HD Links
Huntington's Disease Society
of America
International Huntington
Association
Huntington's Disease Drug
Works
Huntington's Disease
Lighthouse

Nevertheless, the absence of problems is good news.
No surprises have occurred to date, commented Anne Smith, Ph.D., the
Ionis director of clinical development and the individual responsible for
the day-to-day management of the trial.
“It’s blissfully quiet,” Dr. Smith said. “You don’t want surprises in clinical
trials. Most surprises in safety trials are bad surprises. This one is surprisefree to date.”
Also, trial participants had no difficulties with the delivery of the drug via
injections into the spine (so-called intrathecal injections), added Roger
Lane, M.D., the Ionis vice president for neurology clinical development
and one of the designers of the trial.
Watch my reaction after the interview at Ionis headquarters on September
27 in the video below.
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Ionis Phase I HD Trial at Halfway Mark: 'No Surprises So Far' Means
Good News from Gene Veritas on Vimeo.
Phase 2 could start in 2018
“We’re continuing to enroll patients in the study,” Dr. Bennett said. A total
of 36 patients divided into four cohorts – each subsequent cohort taking a
higher dose of IONIS-HTTRx – will participate in the trial.
Ed Wild, M.D., Ph.D., one of the administrators of the trial at University
College London, announced in June at the annual convention of the
Huntington’s Disease Society of America in Baltimore that the third cohort
had received permission to receive the drug. (Click here to watch a video of
Dr. Wild’s presentation.)
“This is a new therapy, and we want to make sure that we’re doing no
harm,” Dr. Bennett emphasized. “Everything is geared towards the safety
of the drug at this stage.”
If Phase 1 confirms safety and tolerability, a year-long Phase 2 trial to
measure efficacy in a larger number of patients likely would start in 2018,
Dr. Bennett said.
Infants on an Ionis SMA drug living longer
The update provided by the Ionis HD team came in the wake of further
validation of the company’s scientific approach.
Ionis makes antisense oligonucleotides (ASOs, artificial strands of DNA)
that alter the expression of genes and can therefore potentially serve as
treatments for genetic diseases. On August 1, Ionis and its partner Biogen
actually halted a Phase 3 trial of an Ionis ASO (nusinersen) in infants with
spinal muscular atrophy (SMA) because the drug, which increases the level
of a key protein, was working so well.
On September 27, Biogen announced that it had completed its application
for priority review of nusinersen by the U.S. Food and Drug
Administration (FDA).
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Like HD, SMA is a genetic neurodegenerative disorder. It primarily affects
children, who “end up becoming paralyzed over time,” Dr. Bennett
explained, and become vulnerable to respiratory infections or other
diseases. Children diagnosed with the most severe form of SMA generally
live less than a year, he said. In a less severe form of SMA, children lose the
ability to walk over time as they grow up, Dr. Bennett added.
“I think the surprising thing that we found – and this was evidence early in
the program – was that we didn’t just stop the decline in these patients,
but we actually reversed it,” Dr. Bennett said. “That was really unexpected.
I should say that they’re not cured of the disease, but they’re doing much
better now than expected. They are surviving longer based on the natural
history of the disease.”
These results demonstrated the body’s capacity to mend once the cause of
a disorder is removed, he observed.
“We’re hopeful that will also occur in Huntington’s,” Dr. Bennett affirmed.
“We have to demonstrate it, but I think there’s a precedent now in these
neurodegenerative diseases. If you remove the insult or the toxicity, you
can recover function.”

Dr. Frank Bennett of Ionis makes a point during discussion of the
company's Phase 1 clinical trial for a Huntington's disease treatment
(photo by Kristina Bowyer, Ionis)
Preparing for the HD clinical study
In the Phase 1 IONIS-HTTRx trial, clinical trial investigators are collecting
some information about the drug’s effect on biomarkers (indicators of a
disease mechanism or drug impact) that may help the team design a
potential Phase 2.
According to Dr. Lane, before a patient receives each of the four planned
doses, the trial administrators collect samples of cerebrospinal fluid (CSF)
that will be used to measure levels of huntingtin protein and a variety of
other protein markers of neuronal injury and inflammation. Patients also
curehd.blogspot.com/2016/10/ionis-phase-i-huntingtons-disease-trial.html
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undergo brain scans to look at the volumes of, and the connectivity
between, different parts of the brain that are known to be affected in HD.
Another biomarker is neurofilament, described by Dr. Bennett as a protein
involved in the cytoskeleton or internal “scaffold” of neurons. “It’s
something very specific to neurons,” said Holly Kordasiewicz, Ph.D., the
Ionis director of neuroscience drug discovery, who participated in selecting
the ASO, researched it in animals, and is developing biomarker tests for
the Phase 1 study. “When the neurons are damaged, neurofilament is
released. In a number of neurodegenerative diseases, neurons are dying
and neurofilament levels go up.”
In HD, brain cells die. In a clinical study, a decrease in neurofilament
would suggest that the drug is protecting neurons, Dr. Kordasiewicz
added.

Ionis Huntington's disease clinical trial planners Dr. Anne Smith (left),
Dr. Roger Lane, and Dr. Holly Kordasiewicz meet with Gene Veritas (in
green shirt) on September 26, 2016, to provide an update on the
company's Phase 1 HD trial (photo by Kristina Bowyer of Ionis)
Getting the design of Phase 2 right
The participants in the IONIS-HTTRx study undergo a battery of tests that
assess memory, thinking, movement, behavior problems, and abilities to
perform every-day activities. This is in preparation for use of such
measures in a potential Phase 2.
“We’re trying to get the information to design the best efficacy study that
we can,” said Dr. Kordasiewicz. “A really sad outcome would be failure of
an efficacy study due to the wrong design, not because the drug’s not
working. You have to be sure you’re picking the right dose and the right
endpoints for the efficacy study. That’s why all the extra stuff goes into
these Phase 1 trials, so that you can get the design right and have the best
shot at giving the drug the best chance at working.”
The large burden of work on patients and trial administrators in Phase
1will ultimately allow Ionis (and its partner Roche) to “simplify” potential
Phase 2 and 3 trials, making them quicker and making it easier for patients
to participate, Dr. Bennett added.
Seeking answers to key questions
This is the first time that an HD gene-silencing drug is going into the
human brain. In animals such as mice and non-human primates, the drug
gets into both the cortex (the outer, main part of the brain, linked to
curehd.blogspot.com/2016/10/ionis-phase-i-huntingtons-disease-trial.html
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consciousness) and the striatum (a part of the brain deep under the surface
that is involved in movement). Both areas are affected by HD.
A key question for researchers: must IONIS-HTTRx reach the striatum to
help alleviate HD?
According to Dr. Kordasiewicz, the latest research in HD mice (conducted
by William Yang, M.D., Ph.D., of the University of California, Los Angeles)
demonstrates that silencing the huntingtin gene in the cortex was more
effective than silencing the gene in the striatum, but that silencing in both
cortex and striatum was the most effective approach.
Another concern of scientists and HD patients and their families involves
the abilities of the ASO, or gene-silencing drug. Should the ASO be
designed to reduce only the so-called “bad,”mutant huntingtin? Or is it
okay to reduce both the bad and the normal version, which is inherited
from the unaffected parent? The IONIS ASO is expected to do the latter.
According to the Ionis HD team, the controversy over this question is
diminishing. Studies in animals support the safety of approaches that
reduce both mutant and normal huntingtin. Additionally, Dr. Guohao
Wang’s work in mice showed that eliminating huntingtin completely in
later life did not have any adverse consequences.
“That was good evidence to support our approach,” said Dr. Lane.
Involving the U.S., thanking patients and families
Many in the HD community have asked: why didn’t Ionis conduct Phase 1
in the United States? And would a potential Phase 2 include Americans?
“I’d be surprised if the U.S. wasn’t involved in a Phase 2 study, as well as
additional countries, but I don’t think we are in a position to say
specifically which countries are going to be involved,” Dr. Bennett
commented. “There were strategic decisions that caused us to go to Europe
and Canada first. It’s not that we want to ignore the U.S.” He explained
that it was faster to start a trial in Canada and Europe.
The Ionis HD team thanked the Phase 1 participants and their families for
their involvement in the Phase 1 study.
“It’s been a very good community and very supportive of our efforts,” said
Dr. Bennett. “We also want to thank them for their patience.”
(Disclosure: I hold a symbolic amount of Ionis shares.)
(Click on the links below for past coverage of the Ionis HD project.)
Chief Huntington's disease drug hunter: 'every confidence first treatments'
in the works
Huntington's disease patients get first dosing in historic Isis
Pharmaceuticals' gene-silencing drug trial
Isis Pharmaceuticals launches historic clinical trial to silence Huntington's
disease gene
Moving toward a potential treatment: Isis, CHDI researchers outline
upcoming Huntington's disease gene-silencing trial
A key new ally in the search for Huntington's disease treatments
Quickening the pace towards a Huntington's disease gene-silencing clinical
trial: pharma giant Roche, Isis enter partnership
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Designing the best drug possible to defeat Huntington's disease
Building a 'laser-guided missile' to attack Huntington's disease
Observing the cure in progress
Posted by Gene Veritas at 8:34 AM
Labels: Anne Smith , ASO , clinical trial , CSF , Frank Bennett , gene-silencing ,
genetic , Holly Kordasiewicz , Huntington's disease , Ionis Pharmaceuticals , IONISHTT-Rx , neurodegenerative , Phase 1 , Roger Lane , treatment
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Anonymous said...
Outstanding work. Thank you for sharing.
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Anonymous said...
Hopeful, indeed. Thank you!!!
6:18 PM, October 22, 2016

Maureen Morehead said...
Hopeful for those of us waiting! Thank you, scientists, and
thank you, Gene.
6:21 PM, October 22, 2016

Unknown said...
Amazing. Could be the answer to so many prayers!
8:59 PM, April 13, 2017
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